Abstracts tagged "IL-6"

Abstract Number: 253 • 2015 ACR/ARHP Annual Meeting
Multiple Serum Cytokine Profiling to Identify Specific Molecular Networks in Attacks of Familial Mediterranean Fever
Tomohiro Koga¹, Kiyoshi Migita², Shuntaro Sato³, Masataka Umeda⁴, Shoichi Fukui⁵, Ayako Nishino⁴, Shinya Kawashiri⁶, Naoki Iwamoto⁵, Kunihiro Ichinose⁵, Mami Tamai⁵, Hideki Nakamura⁵, Tomoki Origuchi⁷, Yukitaka Ueki⁸, Kazunaga Agematsu⁹, Katsumi Eguchi¹⁰ and Atsushi Kawakami⁴, ¹Departments of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ²Department of Rheumatology and Clinical Research Center, Nagasaki Medical Center, Omura, Japan, ³Clinical Research Center, Nagasaki University Hospital, Nagasaki, Japan, ⁴Department of Immunology and Rheumatology, Nagasaki University, Nagasaki, Japan, ⁵Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ⁶Department of Public Health, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ⁷Department of Rehabilitation Sciences, Nagasaki University, Nagasaki, Japan, ⁸Rheumatic and Collagen Disease Center, Sasebo Chuo Hospital, Sasebo, Japan, ⁹Department of Infectious Immunology, Shinshu University, Graduate School of Medicine, Shinshu, Japan, ¹⁰Department of Rheumatology, Sasebo Chuo Hospital, Sasebo, Japan
Background/Purpose: Familial mediterranean fever (FMF) is caused by a number of mutations of the MEFV gene, coding for a protein named pyrin that acts as…
Abstract Number: 798 • 2015 ACR/ARHP Annual Meeting
Keratinocyte-Associated IL-6 Is Elevated in Cutaneous Lupus Rashes and Production of IL-6 By Keratinocytes Is Enhanced in Non-Involved Lupus Skin
Jasmine Stannard¹, Emily Myers², Tamra J. Reed³, Lori Lowe⁴ and J. Michelle Kahlenberg⁵, ¹Int. Medicine/Rheumatology, University of Michigan, Ann Arbor, MI, ²Georgetown University, Washington, DC, ³Internal Medicine, Rheumatology, University of Michigan, Ann Arbor, MI, ⁴Dermatology, University of Michigan, Ann Arbor, MI, ⁵Internal Medicine, Division of Rheumatology, Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI
Background/Purpose: Systemic lupus erythematosus (SLE) is a devastating autoimmune disease with severe complications such as immune-complex mediated nephritis and scarring skin lesions. Treatment modalities for…
Abstract Number: 1153 • 2015 ACR/ARHP Annual Meeting
Colonic Intraepithelial Lymphocytes Produce IL-6 in Response to Resident Bacteria to Modulate Epithelial Barrier Function
Gaurav Mehta¹, Emilie H. Regner², Neha Ohri², Sean P. Colgan² and Kristine A. Kuhn², ¹Division of Rheumatology, University of Colorado School of Medicine, Aurora, CO, ²University of Colorado School of Medicine, Aurora, CO
Background/Purpose: Dysbiosis of colon bacteria has emerged as a likely contributor to diseases such as rheumatoid arthritis and spondyloarthropathies. Interactions between the microbiota and distal…
Abstract Number: 1405 • 2015 ACR/ARHP Annual Meeting
Tocilizumab Serum Levels and Antidrug Antibodies and Its Relationship with Disease Activity in Rheumatic Diseases
Samantha Rodriguez-Muguruza¹, Melania Martínez-Morillo¹, Juana Sanint², Bibiana Quirant Sr.³, Aina Teniente Sr.⁴, Agueda Prior⁵, Anne Riveros-Frutos⁶, Susana Holgado⁷, Maria Lourdes Mateo⁷, Alejandro Olivé⁸, Jeronima Cañellas⁵ and Xavier Tena⁷, ¹Rheumatology, Hospital Universitario Germans Trias i Pujol, Barcelona, Spain, ²Rheumatology, Hospital Universitario Germans Trias i Pujol, Badalona, Spain, ³Immunology, Hospital Universitari Germans Trias i Pujol, Barcelona, Spain, ⁴immunology, Hospital Universitari Germans Trias i Pujol, barcelona, Spain, ⁵Rheumatology, Hospital Universitari Germans Trias i Pujol, Barcelona, Spain, ⁶Microbiology, Hospital Universitario Germans Trias i Pujol, Badalona, Spain, ⁷Rheumatology, Hospital Germans Trias i Pujol, Badalona, Spain, ⁸Hospital Germans Trias i Pujol, Badalona, Spain
Background/Purpose: Tocilizumab (TCZ) is a humanized anti-IL-6 receptor-blocking monoclonal antibody used for the treatment of rheumatoid arthritis (RA), idiopathic juvenile arthritis (IJA) and off-label in…
Abstract Number: 1426 • 2015 ACR/ARHP Annual Meeting
The Effect of Anti-Interleukin-6 Receptor Antibody in Ovariectomized Mice
Sho Kato¹, Hiroki Wakabayashi², Taro Nakagawa³, Yohei Naito³, Takahiro Iino⁴ and Akihiro Sudo⁵, ¹Department of Orthopaedic Surgery, Mie University Graduate School of Medicine, Tsu City, Japan, ²Orthopaedic Surgery, Mie University Graduate School of Medicine, Tsu City, Japan, ³Department of Orthopaedic Surgery, Mie University Graduate School of Medicine, Tsu City, Mie, Japan, ⁴Mie University Graduate School of Medicine, Mie University Graduate School of Medicine, Tsu City, Mie, Japan, ⁵Orthopaedic surgery, Mie University Postgraduate School of Medicine, Tsu-city, Japan
Background/Purpose: Osteoporotic patients with no evidence of fractures sometimes experience vague low back pain. Bone pain associated with bone metastasis may also be related to…
Abstract Number: 1621 • 2014 ACR/ARHP Annual Meeting
A Shift Towards Trans-Signalling Explains Relatively Low CRP Despite an Active Interleukin-6 (IL-6)/IL-6-Receptor (IL-6R) System in SLE
Martyna Skwarek, Babett Heschel, Julia Fantana and Martin Aringer, Medicine III, University Medical Center and Faculty of Medicine at the TU Dresden, Dresden, Germany
Background/Purpose IL-6 has been found increased in SLE, while CRP, which is directly stimulated by IL-6, usually remains low. We therefore analyzed the IL-6/ IL-6…
Abstract Number: 1469 • 2014 ACR/ARHP Annual Meeting
Methotrexate Treatment Reduces Serum IL-6 Level By Decreasing a CD14brightCD16+ Intermediate Non-Classical Subset of Monocytes in RA Patients
Masako Tsukamoto¹, Keiko Yoshimoto², Noriyuki Seta³, Katsuya Suzuki² and Tsutomu Takeuchi², ¹Division of Rheumatology, Department of Internal medicine, Keio University School of Medicine, Tokyo, Japan, ²Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ³Department of Internal Medicine, Keio university, Tokyo, Japan
Background/Purpose It is well known that circulating monocytes are the source of inflammatory cytokines, such as IL-6 and TNFα and newly divided into three subsets…
Abstract Number: 1468 • 2014 ACR/ARHP Annual Meeting
Mechanism of Effectiveness of IL-6 Blockade for Reduction of SAA Production and Amyloid a Deposition in AA Amyloidosis Patients with RA
Kazuyuki Yoshizaki, Osaka University, Osaka, Japan
Background/Purpose AA amyloidosis is a serious complication of chronic inflammatory and infectious diseases resulting from the deposition of amyloid A protein. Serum amyloid A (SAA),…
Abstract Number: 3001 • 2014 ACR/ARHP Annual Meeting
Targeting IL-6 By Both Passive or Active Immunization Strategies Prevents Inflammation-Driven Skin Fibrosis
Jerome Avouac¹, Lucille Desallais², Maxime Fréchet³, Muriel Elhai³, Jean François Zagury² and Yannick Allanore¹, ¹Paris Descartes University, Rheumatology A Department and INSERM U1016, Cochin Hospital, Paris, France, ²Chaire de Bioinformatique, Laboratoire Génomique, Bioinformatique et Applications, EA 4627, Conservatoire National des Arts et Métiers, Paris, France, ³INSERM U1016, Cochin Institute, Paris, France
Background/Purpose: Interleukin 6 (IL-6) is a pleiotropic cytokine involved in inflammatory and autoimmune processes. Preliminary data have suggested that IL-6 might contribute to systemic sclerosis…
Abstract Number: 1015 • 2014 ACR/ARHP Annual Meeting
Mir-9/MCPIP1 Axis Mediated Regulation of IL-6 Expression in Osteoarthritis Chondrocytes
Tariq Haqqi¹, Abdul Haseeb² and Mohammad Shahidul Makki², ¹Anatomy & Neurobiology, Northeast Ohio Medical University, Rootstown, OH, ²Anatomy and Neurobiology, Northeast Ohio Medical University (NEOMED), Rootstown, OH
Background/Purpose Post-transcriptional regulation of cytokine expression is important for maintaining tissue integrity. MCPIP1 was identified as a novel protein, which destabilizes inflammatory cytokines mRNAs via…
Abstract Number: 2905 • 2014 ACR/ARHP Annual Meeting
The IL-6/Th17 Axis Promotes Autoantibody-Associated Autoimmune Valvular Carditis in Mice
Jennifer L. Auger¹, Brianna J. Engelson², Yaya Wang³, Erik J. Peterson⁴ and Bryce A. Binstadt⁵, ¹Center for Immunology and Department of Pediatrics, University of Minnesota, Minneapolis, MN, ²Pediatrics, University of Minnesota, Minneapolis, MN, ³Medicine, University of Minnesota, Minneapolis, MN, ⁴University of Minnesota, Minneapolis, MN, ⁵Pediatric Rheumatology, University of Minnesota, Minneapolis, MN
Background/Purpose: Autoimmune valvular carditis occurs in patients with systemic lupus erythematosus, rheumatoid arthritis and rheumatic fever, but the pathogenic mechanisms remain incompletely defined. Spontaneous autoimmune…
Abstract Number: 1014 • 2014 ACR/ARHP Annual Meeting
Harpagide, a Low Molecular Weight Natural Product, Suppresses IL-1â-Induced IL-6 Expression By Blocking the Activation of p38 MAPK and Transcription Factors CEBPâ and AP-1 in Primary Human Osteoarthritis Chondrocytes
Abdul Haseeb¹ and Tariq Haqqi², ¹Anatomy and Neurobiology, Northeast Ohio Medical University (NEOMED), Rootstown, OH, ²Anatomy & Neurobiology, Northeast Ohio Medical University, Rootstown, OH
Background/Purpose: There is growing evidence that shows the involvement of IL-6 in cartilage degradation during OA. Significant correlation between IL-6 levels in serum as well…
Abstract Number: 2877 • 2014 ACR/ARHP Annual Meeting
Novel Function of Tocilizumab As a Modulator of Interleukin-27-Mediated Anti-Inflammatory Responses
Misato Hashizume¹, Jun Kikuchi², Keiko Yoshimoto² and Tsutomu Takeuchi², ¹Product Research Department, Chugai Pharmaceutical Co., Ltd., Gotemba, Japan, ²Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan
Background/Purpose The immunological roles of interleukin 27 (IL-27) have been reported in the function of regulatory T cells (Treg), monocytes and osteoclasts, and these cells…
Abstract Number: 952 • 2014 ACR/ARHP Annual Meeting
A Phase IIb, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Multicenter Study to Evaluate the Efficacy and Safety of Clazakizumab, an Anti-IL-6 Monoclonal Antibody, in Adults with Active Psoriatic Arthritis
Philip J. Mease¹, A B Gottlieb², A Berman³, E Drescher⁴, J Xing⁵, S Banerjee⁵ and R Wong⁵, ¹Swedish Medical Center and University of Washington, Seattle, WA, ²Tufts Medical Center and Tufts University School of Medicine, Boston, MA, ³Centro Médico Privado de Reumatología, Tucuman, Argentina, ⁴Csolnoky Ferenc Hospital, Veszprém, Hungary, ⁵Bristol-Myers Squibb, Princeton, NJ
Background/Purpose: New treatment options for psoriatic arthritis (PsA) are needed and interleukin-6 (IL-6), a cytokine with a central role in chronic inflammation, is a potential…
Abstract Number: 2823 • 2014 ACR/ARHP Annual Meeting
Comparable Efficacy with Sarilumab Plus Methotrexate in Biologic-Experienced and Biologic-Naïve Patients with Moderate-to-Severe Rheumatoid Arthritis from a Phase 3, Randomized, Double-Blind, Placebo-Controlled, International Study
Roy Fleischmann^1,2, Dennis L. Decktor³, Chunpeng Fan⁴, Hubert Van Hoogstraten⁵ and Mark C Genovese⁶, ¹Metroplax Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX, ²University of Texas Southwestern Medical Center, Dallas, TX, ³Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ⁴Biostatistics, Sanofi, Bridgewater, NJ, ⁵Sanofi, Bridgewater, NJ, ⁶Division of Immunology and Rheumatology, Stanford University Medical Center, Palo Alto, CA
Background/Purpose For patients with prior exposure to tumor necrosis factor-α inhibitor (TNF-I), the likelihood of response to subsequent treatment with a TNF-I declines with the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].